| __timestamp | Axsome Therapeutics, Inc. | Blueprint Medicines Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 7890000 |
| Thursday, January 1, 2015 | 2419289 | 14456000 |
| Friday, January 1, 2016 | 6343648 | 19218000 |
| Sunday, January 1, 2017 | 7206691 | 27986000 |
| Monday, January 1, 2018 | 9351522 | 47928000 |
| Tuesday, January 1, 2019 | 13598030 | 96388000 |
| Wednesday, January 1, 2020 | 28896749 | 157743000 |
| Friday, January 1, 2021 | 66646205 | 195293000 |
| Saturday, January 1, 2022 | 159253661 | 237374000 |
| Sunday, January 1, 2023 | 323123000 | 295141000 |
| Monday, January 1, 2024 | 359272000 |
In pursuit of knowledge
In the competitive landscape of biotechnology, operational efficiency is paramount. Over the past decade, Blueprint Medicines Corporation and Axsome Therapeutics, Inc. have demonstrated distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Blueprint Medicines saw a staggering 3,600% increase in SG&A costs, peaking at nearly $295 million in 2023. Meanwhile, Axsome Therapeutics experienced an even more dramatic rise, with expenses surging by over 23,000%, reaching approximately $323 million in the same year.
This trend reflects the aggressive expansion and strategic investments both companies have undertaken to bolster their market positions. As these biotech giants continue to innovate, understanding their financial strategies offers valuable insights into their future growth potential. Investors and industry analysts should closely monitor these trends to gauge the companies' operational health and strategic direction.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Selling, General, and Administrative Costs: Pfizer Inc. vs Axsome Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Genmab A/S and Axsome Therapeutics, Inc.
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Cytokinetics, Incorporated and Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Axsome Therapeutics, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Axsome Therapeutics, Inc. and MannKind Corporation